{"id":"https://openalex.org/W7222922035","doi":"https://doi.org/10.1002/bcp.70844","title":"Absorption, distribution, metabolism and excretion of londamocitinib after single\u2010dose inhaled, intravenous and oral administration in healthy participants","display_name":"Absorption, distribution, metabolism and excretion of londamocitinib after single\u2010dose inhaled, intravenous and oral administration in healthy participants","publication_year":2026,"publication_date":"2026-10-19","ids":{"openalex":"https://openalex.org/W7222922035","doi":"https://doi.org/10.1002/bcp.70844","pmid":"https://pubmed.ncbi.nlm.nih.gov/42896884"},"language":"en","primary_location":{"id":"doi:10.1002/bcp.70844","doi":"https://doi.org/10.1002/bcp.70844","is_oa":true,"landing_page_url":"https://doi.org/10.1002/bcp.70844","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70844","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","datacite","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70844","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089248728","display_name":"Camille Riff","orcid":"https://orcid.org/0000-0003-3697-466X","observed_orcids":["https://orcid.org/0000-0003-3697-466X"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":true,"raw_author_name":"Camille Riff","raw_affiliation_strings":["Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D AstraZeneca  Gothenburg Sweden"],"raw_orcid":"https://orcid.org/0000-0003-3697-466X","affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D AstraZeneca  Gothenburg Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020279152","display_name":"Peter Bold","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Peter Bold","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D AstraZeneca  Gothenburg Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D AstraZeneca  Gothenburg Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033278480","display_name":"Maria Heijer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Maria Heijer","raw_affiliation_strings":["Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D AstraZeneca  Gothenburg Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D AstraZeneca  Gothenburg Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029932557","display_name":"Ryan A. Bragg","orcid":"https://orcid.org/0000-0002-7545-8628","observed_orcids":["https://orcid.org/0000-0002-7545-8628"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ryan A. Bragg","raw_affiliation_strings":["Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D AstraZeneca  Cambridge UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D AstraZeneca  Cambridge UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159032887","display_name":"Danielle Steele","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Danielle Steele","raw_affiliation_strings":["Early Product Development, Pharmaceutical Sciences, BioPharmaceuticals R&D AstraZeneca  Macclesfield UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Early Product Development, Pharmaceutical Sciences, BioPharmaceuticals R&D AstraZeneca  Macclesfield UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026773546","display_name":"Tina Jellesmark Jensen","orcid":"https://orcid.org/0009-0008-4696-643X","observed_orcids":["https://orcid.org/0009-0008-4696-643X"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Tina Jellesmark Jensen","raw_affiliation_strings":["Clinical Development, R&I, BioPharmaceuticals R&D AstraZeneca  Gothenburg Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, R&I, BioPharmaceuticals R&D AstraZeneca  Gothenburg Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072021354","display_name":"Davinder P. S. Dosanjh","orcid":"https://orcid.org/0000-0002-9169-5607","observed_orcids":["https://orcid.org/0000-0002-9169-5607"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Davinder P. S. Dosanjh","raw_affiliation_strings":["Birmingham Acute Care Research, Institute of Inflammation and Ageing University of Birmingham  Birmingham UK","Clinical Development, R&I, BioPharmaceuticals R&D AstraZeneca  Cambridge UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Birmingham Acute Care Research, Institute of Inflammation and Ageing University of Birmingham  Birmingham UK","institution_ids":["https://openalex.org/I79619799"]},{"raw_affiliation_string":"Clinical Development, R&I, BioPharmaceuticals R&D AstraZeneca  Cambridge UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159063039","display_name":"Sabrina I. Hanswijk\u2010Bartelds","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I148297040","display_name":"Netherlands Organisation for Applied Scientific Research","ror":"https://ror.org/01bnjb948","country_code":"NL","type":"nonprofit","lineage":["https://openalex.org/I148297040"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Sabrina I. Hanswijk\u2010Bartelds","raw_affiliation_strings":["The Netherlands Organization for Applied Scientific Research (TNO)  The Hague The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Organization for Applied Scientific Research (TNO)  The Hague The Netherlands","institution_ids":["https://openalex.org/I148297040"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020874937","display_name":"Esther van Duijn","orcid":"https://orcid.org/0009-0000-9704-4277","observed_orcids":["https://orcid.org/0009-0000-9704-4277"]},"institutions":[{"id":"https://openalex.org/I148297040","display_name":"Netherlands Organisation for Applied Scientific Research","ror":"https://ror.org/01bnjb948","country_code":"NL","type":"nonprofit","lineage":["https://openalex.org/I148297040"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Esther van Duijn","raw_affiliation_strings":["The Netherlands Organization for Applied Scientific Research (TNO)  The Hague The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Organization for Applied Scientific Research (TNO)  The Hague The Netherlands","institution_ids":["https://openalex.org/I148297040"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090294435","display_name":"Elwin R. Verheij","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I148297040","display_name":"Netherlands Organisation for Applied Scientific Research","ror":"https://ror.org/01bnjb948","country_code":"NL","type":"nonprofit","lineage":["https://openalex.org/I148297040"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Elwin R. Verheij","raw_affiliation_strings":["The Netherlands Organization for Applied Scientific Research (TNO)  The Hague The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Netherlands Organization for Applied Scientific Research (TNO)  The Hague The Netherlands","institution_ids":["https://openalex.org/I148297040"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012486938","display_name":"Somasekhara R. Menakuru","orcid":"https://orcid.org/0009-0005-7028-7697","observed_orcids":["https://orcid.org/0009-0005-7028-7697"]},"institutions":[{"id":"https://openalex.org/I4405267629","display_name":"Quotient Sciences Limited (United Kingdom)","ror":"https://ror.org/03ncz2v38","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405267629"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Somasekhara Menakuru","raw_affiliation_strings":["Quotient Sciences  Nottingham UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quotient Sciences  Nottingham UK","institution_ids":["https://openalex.org/I4405267629"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5122825805","display_name":"Rod Hughes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rod Hughes","raw_affiliation_strings":["Clinical Development, R&I, BioPharmaceuticals R&D AstraZeneca  Cambridge UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, R&I, BioPharmaceuticals R&D AstraZeneca  Cambridge UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087603780","display_name":"Helena Dahlb\u00e4ck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Helena Dahlb\u00e4ck","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D AstraZeneca  Gothenburg Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D AstraZeneca  Gothenburg Sweden","institution_ids":["https://openalex.org/I4210143795"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5089248728"],"corresponding_institution_ids":["https://openalex.org/I4210143795"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":{"value":4780,"currency":"USD","value_usd":4780},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.77380822,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.5717999935150146,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.5717999935150146,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.2728999853134155,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.04809999838471413,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/jak1-inhibitor","display_name":"JAK1 inhibitor","score":0.9139999747276306},{"id":"https://openalex.org/keywords/pulmonary-drug-delivery","display_name":"pulmonary drug delivery","score":0.8149999976158142},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8569999933242798},{"id":"https://openalex.org/keywords/adme","display_name":"ADME","score":0.6790000200271606},{"id":"https://openalex.org/keywords/absolute-bioavailability","display_name":"absolute bioavailability","score":0.9549999833106995},{"id":"https://openalex.org/keywords/fecal-excretion","display_name":"fecal excretion","score":0.7680000066757202},{"id":"https://openalex.org/keywords/asthma","display_name":"asthma","score":0.5619999766349792},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.6759999990463257}],"concepts":[{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.7091000080108643},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6704999804496765},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.6643000245094299},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6617000102996826},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.6431999802589417},{"id":"https://openalex.org/C2780026642","wikidata":"https://www.wikidata.org/wiki/Q40924","display_name":"Urine","level":2,"score":0.6371999979019165},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.6370999813079834},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6348999738693237},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6251999735832214},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6061999797821045},{"id":"https://openalex.org/C61716771","wikidata":"https://www.wikidata.org/wiki/Q496","display_name":"Feces","level":2,"score":0.4537999927997589},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.44519999623298645},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.35269999504089355},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.3391000032424927},{"id":"https://openalex.org/C2776093070","wikidata":"https://www.wikidata.org/wiki/Q621636","display_name":"Route of administration","level":2,"score":0.3061999976634979},{"id":"https://openalex.org/C2776954882","wikidata":"https://www.wikidata.org/wiki/Q840343","display_name":"Inhalation","level":2,"score":0.2824000120162964},{"id":"https://openalex.org/C3019361228","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral dose","level":3,"score":0.2775999903678894},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.2603999972343445},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2574999928474426}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1002/bcp.70844","doi":"https://doi.org/10.1002/bcp.70844","is_oa":true,"landing_page_url":"https://doi.org/10.1002/bcp.70844","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70844","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:42896884","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42896884","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Journal Article"},{"id":"doi:10.82135/tno-1036925","doi":"https://doi.org/10.82135/tno-1036925","is_oa":true,"landing_page_url":"https://doi.org/10.82135/tno-1036925","pdf_url":null,"source":{"id":"https://openalex.org/S7407055233","display_name":"TNO Repository","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"doi:10.1002/bcp.70844","doi":"https://doi.org/10.1002/bcp.70844","is_oa":true,"landing_page_url":"https://doi.org/10.1002/bcp.70844","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bcp.70844","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F3827138902","display_name":"AstraZeneca M\u00f6lndal","ror":"https://ror.org/04wwrrg31"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7222922035.pdf","grobid_xml":"https://content.openalex.org/works/W7222922035.grobid-xml"},"referenced_works_count":13,"referenced_works":["https://openalex.org/W152943885","https://openalex.org/W1990938178","https://openalex.org/W2091711716","https://openalex.org/W2098176676","https://openalex.org/W2127354384","https://openalex.org/W2133849435","https://openalex.org/W2891309258","https://openalex.org/W2973062654","https://openalex.org/W2981701057","https://openalex.org/W4316022307","https://openalex.org/W4386948927","https://openalex.org/W4388894525","https://openalex.org/W7122513039"],"related_works":["https://openalex.org/W4416634614","https://openalex.org/W4416634408","https://openalex.org/W4387980195","https://openalex.org/W4403859515","https://openalex.org/W2395237281","https://openalex.org/W2047514526","https://openalex.org/W2777899369","https://openalex.org/W2054557066","https://openalex.org/W4212890519","https://openalex.org/W2991290002"],"abstract_inverted_index":{"Aim":[0],"Londamocitinib":[1],"(AZD4604)":[2],"is":[3],"an":[4,103,245],"inhaled,":[5],"selective":[6],"Janus":[7],"kinase":[8],"1":[9,101],"(JAK1)":[10],"inhibitor":[11],"in":[12,50,99,126,141,145,153,157,180,192,235],"development":[13],"for":[14,167,184],"asthma.":[15],"This":[16],"open\u2010label,":[17],"two\u2010part,":[18],"phase":[19],"I":[20],"clinical":[21],"study":[22],"(NCT06157255)":[23],"used":[24],"a":[25,84,119],"radiolabelled":[26],"microtracer":[27],"approach":[28],"to":[29],"evaluate":[30],"the":[31,35,189,220,231],"absolute":[32],"bioavailability":[33,160],"and":[34,39,47,53,65,71,102,143,155,166,182,186,196,209,216,227,238,248],"absorption,":[36,215],"distribution,":[37],"metabolism":[38],"excretion":[40,218],"(ADME)":[41],"of":[42,89,107,123,132,161,177,188,223],"inhaled":[43,121,168,208],"londamocitinib":[44,125,163,173,212,226],"after":[45,136,194],"intravenous":[46,104,148,197],"oral":[48,86,137,162,195,210],"administration":[49,169,198],"healthy":[51],"male":[52],"female":[54],"participants":[55],"(":[56],"n":[57],"=":[58],"8).":[59],"Methods":[60],"Pharmacokinetics,":[61],"safety,":[62],"metabolic":[63],"profile":[64],"metabolite":[66,228],"identification":[67],"from":[68],"plasma,":[69,236],"urine,":[70],"faecal":[72,217],"samples":[73],"were":[74,204,230],"assessed":[75],"employing":[76],"highly":[77],"sensitive":[78],"accelerator":[79],"mass":[80],"spectrometry.":[81],"Participants":[82],"received":[83],"single":[85,120],"4\u2010mg":[87],"dose":[88,106,122,191],"[":[90,96,108,114],"14":[91,97,109,115],"C]londamocitinib":[92,110],"(NMT":[93,111],"37.0":[94,112],"kBq":[95,113],"C])":[98],"Part":[100,127],"30\u2010\u03bcg":[105],"C]),":[116],"followed":[117],"by":[118],"3\u2010mg":[124],"2.":[128],"Results":[129],"Mean":[130],"recovery":[131,150],"total":[133],"radioactive":[134],"material":[135],"dosing":[138],"was":[139,151,164,170],"76.3%":[140],"faeces":[142,154],"8.7%":[144],"urine.":[146,158],"After":[147],"dosing,":[149,211],"67.3%":[152],"16.0%":[156],"Absolute":[159],"40.4%":[165],"62.5%.":[171],"Unchanged":[172,225],"constituted":[174],"approximately":[175],"70%":[176],"circulating":[178],"radioactivity":[179],"plasma":[181],"accounted":[183],"47.8%":[185],"28.4%":[187],"administered":[190],"excreta":[193],"respectively.":[199],"No":[200],"new":[201],"safety":[202,247],"signals":[203],"observed.":[205],"Conclusion":[206],"Following":[207],"demonstrated":[213],"rapid":[214],"as":[219],"principal":[221],"route":[222],"elimination.":[224],"M6":[229],"major":[232],"entities":[233],"present":[234],"urine":[237],"faeces.":[239],"Londamocitinib,":[240],"at":[241],"these":[242],"doses,":[243],"exhibited":[244],"acceptable":[246],"tolerability":[249],"profile.":[250]},"counts_by_year":[],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2026-10-20T00:00:00"}